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i.org/1disease (CVD) events in high-risk patients attaining low levels of low-density lipoprotein
(LDL), as measured by LDL particle number (LDL-P) versus low LDL cholesterol (LDL-C).
Here, we investigated the cost effectiveness of LDL-lowering therapy guided by LDL-P.
Patients were selected from the HealthCore Integrated Research Database and followed
for 12 to 36 months. Patients who achieved LDL-P <1,000 nmol/l were placed into the LDL-
P cohort, whereas those without LDL-P tests, but who achieved LDL-C <100 mg/dl, were
placed into the LDL-C cohort. CVD-related costs included all health plan paid amounts
related to CVD events or lipid management. Cost effectiveness was assessed through in-
cremental cost-effectiveness ratios, deﬁned as difference in total costs across the cohorts
divided by difference in CVD events, measured over follow-up. Each cohort included 2,094,
1,242, and 705 patients over 12-, 24-, and 36-month follow-up. Patients in the LDL-P cohort
received more aggressive lipid-lowering therapy and had fewer CVD events during follow-
up compared to patients in the LDL-C cohort. This led to greater pharmacy costs and lower
medical costs over time. Incremental cost-effectiveness ratio estimates ranged from $23,131
per CVD event avoided at 12 months to $3,439 and L$4,555 at 24- and 36-month follow-
up, suggesting a high likelihood that achieving LDL-P <1,000 nmol/l is cost effective. In
conclusion, LDL-lowering therapy guided by LDL-P was demonstrated to be cost effective,
with greater clinical and economic beneﬁt seen over longer time horizons and with the
increased use of generic statins.  2016 The Author(s). Published by Elsevier Inc. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/). (Am J Cardiol 2016;-:-e-)The potential beneﬁt of attaining prespeciﬁed low-
density lipoprotein (LDL) levels, as measured by nuclear
magnetic resonance spectroscopy LDL particle number
(LDL-P) versus LDL cholesterol (LDL-C) measured by a
standard lipid panel, was previously reported using data
from the HealthCore Integrated Research Database.1 High-
risk subjects achieving an LDL-P target <1,000 nmol/l
received more intensive lipid-lowering therapy and experi-
enced signiﬁcant reductions in the risk of cardiovascular
disease (CVD) events over 12-, 24-, and 36-month follow-
up compared to subjects attaining an LDL-C target
<100 mg/dl. To help put the previous clinical ﬁndings in
economic context, we examined differences in health care
costs between the 2 target groups and performed a cost-
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Methods
This study used the same data set on which the previous
clinical analysis was conducted, and details of the method
have been published previously.1 Here, we summarize the
key elements and describe the outcomes and statistical
methods pertaining to the present economic analysis.
This was a retrospective, observational study using
administrative claims and electronic laboratory results from
the HealthCore Integrated Research Database, augmented
with LDL-P and lipid panel data from LipoScience, Inc.
(now LabCorp).1 Patients had to be enrolled in a commer-
cial health plan or Medicare Advantage to be included in the
study. Adults (aged 18 years) who had 1 electronic
LDL-P result from January 1, 2006, to September 30, 2012,
were included in the LDL-P cohort. Patients without LDL-P
measurements but who had LDL-C results were included in
the LDL-C cohort. Index date was set as the earliest
observed date with LDL-P <1,000 nmol/l or LDL-C
<100 mg/dl. All patients were required to have at least
6 months of continuous medical and pharmacy health plan
enrollment before the index date to establish baseline
medication use and co-morbidities. The analysis focused on
high-risk patients with previous CVD or CVD riskccess article
4.0/).
www.ajconline.org
2 The American Journal of Cardiology (www.ajconline.org)equivalents. Patients were subset into overlapping 12-, 24-,
and 36-month cohorts based on the length of their available
follow-up enrollment after the index date. Patients were
observed until the end of each follow-up period or death (as
recorded in the Social Security Administration’s Death
Master File), whichever occurred ﬁrst.
Acute CVD and stroke events occurring in inpatient or
emergency department settings were assessed among patient
subgroups with 12-, 24-, and 36-month follow-up. CVD
(which included myocardial infarction, unstable angina, and
revascularization) and stroke were identiﬁed by Interna-
tional Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation diagnosis and procedural codes and Common
Procedural Terminology codes on medical claims.
The evaluation of health care costs included CVD-
related health plan paid medical costs and pharmacy
costs observed over 12-, 24-, and 36-month follow-up.
CVD-related medical costs were derived from claims for
medical encounters in which a diagnosis code for dyslipi-
demia was observed (for outpatient visits) or a diagnosis
for CVD (acute CVD, stroke, transient ischemic attack,
peripheral vascular disease) was observed (for inpatient
and emergency department visits). CVD-related pharmacy
costs were derived from outpatient pharmacy claims for
observed lipid-altering medications. All costs were
adjusted to 2012 dollars.
For the CEA, costs were summed across all patients in
each cohort. Effectiveness was deﬁned as the total number
of CVD events avoided (number of events in the LDL-C
cohort minus number of events in the LDL-P cohort),
allowing for multiple events per patient. Cost effectiveness
was assessed by calculating an incremental cost-
effectiveness ratio (ICER; deﬁned as the difference in total
costs across the LDL-P and LDL-C cohorts, divided by the
difference in effectiveness) and comparing it to a range of
willingness-to-pay (WTP) thresholds, which represent the
maximum amount of resources the decision-maker (such as
a health plan) is willing to commit to avoid 1 event.2 Such
thresholds may vary across decision-makers and over time.
Cost-effectiveness acceptability curves were created to
present the likelihood of LDL-P targeting being cost effec-
tive for a wide range of WTP thresholds.3 No discounting
was used because of the short time horizon.
Statistical signiﬁcance was deﬁned as a p value <0.05.
Baseline patient characteristics and CVD events over
follow-up were compared between the LDL-C and LDL-P
cohorts separately at 12, 24, and 36 months, using inde-
pendent t tests or Wilcoxon rank-sum tests for continuous
variables and the chi-square tests for categorical variables.
Unadjusted Cox proportional hazards models were used to
estimate relative CVD event risk reduction. Absolute risk
reduction rates were calculated as the difference in cohort
incidence rates. Number of patients needed to treat to LDL-
P target to avoid 1 CVD event equaled the inverse of the
absolute risk reduction rate.
Univariate analysis of per-patient costs suggested the
presence of outliers in both cohorts. To address this issue,
Winsorization was implemented at the ﬁfth and ninety-ﬁfth
percentile, and the Winsorized costs were used for all
remaining analyses.4 Generalized linear models with a log
link and gamma distribution were used to estimatedifferences in CVD-related per-patient costs across cohorts
to account for cost skewness.5
Before the comparison of events and costs, and the CEA,
stringent 1:1 propensity score matching was used to balance
the baseline demographic and co-morbidity differences be-
tween each of the LDL-P and LDL-C cohorts.6,7 Thus, 3
separate matches were conducted corresponding to sub-
cohorts of LDL-C and LDL-P patients with 12-, 24-, and 36-
month follow-up. Differences in treatment patterns and lipid
values at baseline were left intact.
Sampling uncertainty in the ICER was estimated through
scatter plots and cost-effectiveness acceptability curves
based on 5,000 nonparametric bootstrap samples.2
Percentile-based 95% conﬁdence intervals for total cost
and event differences, as well as for the ICER, were derived
from the bootstrap. In addition, the ICER was reestimated
under various alternative scenarios to further explore
robustness:
(1) Inclusion of patient paid costs (vs health plan paid
costs only);
(2) Using all-cause plan paid costs (vs CVD-related costs
only); and
(3) Assuming a 75% or 90% cost reduction for ator-
vastatin and rosuvastatin due to availability of
generic versions (vs branded costs as captured in the
available data set; see the Supplementary Data for
more details).
Results
Each matched cohort (LDL-C and LDL-P) included
2,094, 1,242, and 705 patients over 12-, 24-, and 36-month
follow-up, respectively, as previously described.1 Table 1
describes baseline characteristics and follow-up outcomes
after matching. Mean age was 56 years, and w42% of pa-
tients were women. Between-group differences in laboratory
values and medication utilization were expressly retained
and not controlled for during the matching process. In
particular, greater utilization of lipid-lowering medications
and maximum potency statins was observed among patients
in the LDL-P cohort. The incidence of CVD events was
lower among patients in each LDL-P subcohort than among
patients in each LDL-C subcohort. The relative risk reduc-
tion for LDL-P patients was approximately 22% to 25%
across all 3 timeframes. Number of patients needed to treat
ranged from 23 to 55, with the lowest number correspond-
ing to the highest absolute risk reduction rate observed
among patients with 36 months of follow-up.
Compared to the LDL-C cohort, medical costs in the
LDL-P cohort were typically lower, whereas pharmacy
costs were greater (because of more medication use) during
all three follow-up timeframes, irrespective of adjustment
for outliers. Differences in medical costs increased over time
such that, in the 24- and 36-month samples, greater phar-
macy costs among LDL-P patients were offset resulting in
similar total costs between cohorts (Supplementary Table 1).
The results of the primary CEA and the sensitivity analysis
are presented in Table 2. At 12 months, total costs were
$393,226 higher in the LDL-P cohort, where there were 17
fewer CVD events observed compared to the LDL-C cohort,
resulting in an ICER of $23,131 per event avoided. The
Table 1
Patient baseline characteristics and follow-up CVD event risk
Variable 12 months 24 months 36 months
LDL-P Cohort
(n¼2,094)
LDL-C Cohort
(n¼2,094)
p-value LDL-P Cohort
(n¼1,242)
LDL-C Cohort
(n¼1,242)
p-value LDL-P Cohort
(n¼705)
LDL-C Cohort
(n¼705)
p-value
Age in years, mean (SD) 57 (11) 56 (11) 0.055 57 (11) 56 (11) 0.054 57 (11) 57 (11) 0.872
Female 899 (43%) 881 (42%) 0.574 526 (42%) 539 (43%) 0.598 302 (43%) 320 (45%) 0.334
Diabetes mellitus 1,183 (57%) 1,198 (57%) 0.640 692 (56%) 715 (3%) 0.352 407 (58%) 408 (58%) 0.957
Cardiovascular disease 1,313 (63%) 1,279 (61%) 0.279 778 (63%) 776 (63%) 0.934 425 (60%) 396 (56%) 0.117
Comorbidity index, mean (SD) 1.04 (1.3) 1.12 (1.2) 0.043 1.03 (1.3) 1.10 (1.3) 0.175 1.04 (1.2) 1.07 (1.2) 0.616
Lipid-lowering medications,
patients with 1 ﬁll
1,524 (73%) 1,464 (70%) 0.040 912 (73%) 838 (68%) 0.001 500 (71%) 485 (69%) 0.384
Statin high potency (40-50%
LDL-C reduction)
794 (38%) 706 (34%) 0.005 460 (37%) 423 (34%) 0.001 252 (36%) 229 (33%) 0.196
Statin highest potency (>50%
LDL-C reduction)
236 (11%) 125 (6%) <.001 136 (11%) 63 (5%) <.001 72 (10%) 24 (3%) <.001
LDL-P, mean (SD) 858 (106) - - 862 (105) - - 864 (106) - -
LDL-C, mean (SD) 73 (21) 79 (15) <.001 73 (21) 80 (14) <.001 73 (22) 79 (15) <.001
HDL-C, mean (SD) 54 (15) 50 (14) <.001 53 (14) 47 (13) 0.001 52 (14) 49 (14) 0.001
Patients with 1 CVD event 130 (6.2%) 168 (8.0%) 0.022 135 (11%) 171 (14%) 0.028 103 (15%) 134 (19%) 0.027
Hazard Ratio (95% CI) 0.77 (0.61-0.96) 0.021 0.78 (0.62-0.98) 0.031 0.75 (0.58-0.97) 0.029
Absolute Risk Reduction/Number
Needed to Treat
1.8% / 55 - 2.9% / 34 - 4.4% / 23 -
CI ¼ conﬁdence interval; CVD ¼ cardiovascular disease; HDL-C ¼ high density lipoprotein cholesterol; LDL-C ¼ low density lipoprotein cholesterol;
LDL-P ¼ low density lipoprotein particle number; SD ¼ standard deviation.
Preventive Cardiology/The Cost Effectiveness of LDL-P 3uncertainty surrounding this point estimate is visualized in a
scatter plot (Figure 1, top-left panel), in which each dot rep-
resents an ICER estimate from 1 of the 5,000 bootstraps. The
point estimate of the ICER and 72% of the replicates fell into
the top-right quadrant, indicating greater effectiveness (fewer
events) and greater costs for patients in the LDL-P cohort (vs
those in the LDL-C cohort). Approximately 28% of replicates
fell into the top-left quadrant, with lower effectiveness and
greater costs in the LDL-P cohort.
To determine cost effectiveness, the ICER was compared
to a wide range of WTP thresholds to avoid 1 CVD event by
means of a cost-effectiveness acceptability curve. In
Figure 1, the top-right panel presents such a curve for the
12-month sample. As WTP approaches $20,000, the likeli-
hood that the achievement of LDL-P <1,000 nmol/l is a
more cost-effective treatment strategy relative to a strategy
of achieving LDL-C <100 mg/dl is 50%. This cost-
effectiveness likelihood for LDL-P target achievement at-
tains a maximum of close to 70% as WTP reaches $100,000.
At the 24- and 36-month time horizons, the event differ-
ences further increase compared to 12 months (i.e., there is a
larger number of events observed in patients in each LDL-C
subcohort relative to each corresponding LDL-P subcohort),
whereas the cost differences narrow (i.e., the incremental total
costs between corresponding LDL-P and LDL-C subcohorts
are reduced), leading to ICER point estimates of $3,439 (24
months) and $4,555 (36 months). Figure 1 illustrates the
underlying changes, with the ICER cloud expanding and
moving into the bottom-right quadrant, where LDL-P-guided
treatment is both more effective and less costly than LDL-Ce
guided treatment. This also affects the cost-effectiveness
acceptability curves, by shifting them upward such that the
likelihood of LDL-P <1,000 nmol/l being a cost-effective
treatment strategy versus achievement of LDL-C <100 mg/dlincreases over the entire WTP range. For example, at
24 months, attaining LDL-P<1,000 nmol/l is estimated to be
cost effectivewith a probability of 90% for aWTPof $20,000.
These results were robust under alternative assumptions
as explored in the sensitivity analysis. As summarized in
Table 2, the inclusion of patient paid costs increased the
ICER to $31,152, whereas analysis using all-cause costs
resulted in lower total costs in the LDL-P cohort and a
negative ICER (with both lower costs and higher effec-
tiveness in the LDL-P cohort). Finally, we examined a
scenario in which atorvastatin and rosuvastatin pricing was
reduced 75% or 90% to reﬂect more current generic statin
prices. Because high-potency statins were used more often
in the LDL-P cohort (Table 1), this price reduction yielded a
diminished cost difference across the 2 cohorts. As illus-
trated by the broken line in Figure 1, when atorvastatin and
rosuvastatin pricing is reduced by 75%, the ICER is lowered
and the cost-effectiveness acceptability curve rotates up-
ward, increasing the likelihood of cost effectiveness for a
treatment strategy that targets LDL-P <1,000 nmol/L at
lower WTP values. Most of the beneﬁt is realized with a
75% reduction (vs 90%).
Discussion
We previously published data from the ﬁrst real-world
analysis of a large, commercially insured, high-risk patient
population demonstrating that more intense lipid-lowering
therapy guided by LDL-P resulted in fewer CVD events
over 12-, 24-, and 36-month follow-up.1 Here, we evaluated
the cost effectiveness of such a treatment strategy relative to
“standard care” of LDL-C management to a target of
100 mg/dl. The more intense therapy tended to be
more costly to the health plan at 12-month, cost equivalent
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4 The American Journal of Cardiology (www.ajconline.org)at 24-month, and potentially cost saving at 36-month
follow-up because of reductions in medical expenses from
fewer CVD events.
Point estimates of the ICER ranged from $23,131 per
event avoided at 12 months to $3,439 and $4,555 at 24
and 36 months, respectively. Thus, LDL-Peguided treat-
ment is likely to be highly cost effective at commonly used
WTP thresholds, as shown in the cost-effectiveness
acceptability curves. Previous studies of interventions to
manage CVD have used a wide range of WTP thresholds for
1 CVD event avoided, ranging from $50,000 to
$500,000.8e10 Although use of a single threshold may
appear more practical, it has been argued that thresholds
should vary across payers, populations, and interventions.11
Therefore, we present information about the likelihood of
the cost effectiveness of LDL-Peguided treatment across a
range of thresholds.
Because high-potency statins were used more often in the
LDL-P cohort and such medications were largely sold as
branded drugs during the study period from 2006 to 2012, a
sensitivity analysis was conducted to explore the inﬂuence
of generic statin pricing. Reducing the costs of atorvastatin
and rosuvastatin by 75% lowered the ICER at every point in
follow-up and increased the potential for cost effectiveness
at lower WTP thresholds.
This analysis is consistent with an earlier analysis
based on clinical data from the Multi-Ethnic Study of
Atherosclerosis, which found managing to LDL-P, either
alone or in combination with LDL-C, to be less expensive
and to increase quality-adjusted life-years in comparison
with LDL-Ceonly management.12 Similarly, using the
detailed Archimedes simulation model of disease progres-
sion and health care delivery, LDL-Peguided statin therapy
was estimated to reduce the risk of CVD events to a greater
extent than therapy guided by LDL-C alone and to be cost
effective or cost saving for high-risk patients.13
The present analysis provides new insights that may be
helpful in clinical practice. Multiple societies have issued
recommendations to aid clinicians in the management of
their patients’ LDL-related CVD risk.14e20 All involve
assessment of CVD risk status, initiation of therapy using
clinically proven drugs (i.e., statins), followed by varying
recommendations to monitor LDL response to therapy.
Concern exists that individual care may not be optimized if
management is viewed as complete after the initiation of
statin therapy. Because of frequent discordance between
cholesterol and particle number measurements of LDL
quantity,21e24 and given that CVD risk tracks with LDL-P
rather than LDL-C in the setting of discordance,22,24,25
several groups have endorsed the use of LDL-P to judge
response and optimize individual therapy, even if LDL-C
and noneHDL-C are at target levels.16e20 Our previous
ﬁndings from a real-world population of patients with CVD
showed LDL-Peguided therapy is associated with a
reduction in CVD events.1 The present analysis suggests
this approach is likely to be cost effective as well, providing
information that can be critical for the decision-making of
physicians, payers, and patients.
We await the results of clinical trials evaluating the effect
of proprotein convertase subtilisin/kexin type 9 inhibitors on
CVD events.26 Currently, these agents are indicated for use
Figure 1. ICER scatter plots and cost-effectiveness acceptability curves.
Preventive Cardiology/The Cost Effectiveness of LDL-P 5in patients with clinical CVD or familial hypercholester-
olemia who, on maximally tolerated statin therapy, are
deemed to need further LDL reduction. This requires LDL
monitoring to select eligible patients and to adjudicate
response to therapy. If PCSK9 inhibitors demonstrate
signiﬁcant reduction in CVD risk, there is a potential for
LDL-P assessments to be valuable in optimizing individual
therapy. A similar opportunity exists based on the expected
availability and therefore greater utilization of a generic
form of Zetia (ezetimibe) in the United States starting in late
2016.27
Limitations of this analysis include the following: The
study sample was taken from 1 large US commercial health
plan, and results may not be generalizable to patients
enrolled in different plans or outside the United States.
Propensity score matching was used to simulate randomi-
zation into treatment cohorts based on observed character-
istics; it is possible selection bias based on unobservable
variables remained. In particular, because the study used aclaims database, no information was available on several
factors which could inﬂuence patient selection and out-
comes (e.g., race, family history of CVD, smoking status,
weight, diet, exercise, socioeconomic status, physician
preferences, overall clinical quality of care). However, many
of these factors may plausibly be distributed equally across
the LDL-P and LDL-C cohorts and thus would have little
effect on outcome comparisons. Variations in patient
medication adherence to either lipid-lowering drugs or other
cardioprotective medicines between cohorts were not
assessed. This analysis was limited to direct costs; indirect
costs, such as lost productivity, were not included.Acknowledgment: The authors acknowledge Peter P.
Toth, MD, PhD (Johns Hopkins University School of
Medicine, Baltimore, Maryland) and Terry A. Jacobson, MD
(Emory University, Atlanta, Georgia) for their input into the
clinical analysis on which this study is built and their
6 The American Journal of Cardiology (www.ajconline.org)contribution to a presentation of partial results from the cost
analysis at AMCP’s 27th Annual Meeting and Expo in San
Diego, California, April 7 to 10, 2015.
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